[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380222":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":38,"responsibleParty":58,"collaborators":60,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":77,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AIS before EVT group",null,"This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)",[13],"Genetic: Sequencing of circRNA\u002FlncRNA\u002FmiRNA",{"label":15,"type":10,"description":16,"interventionNames":17},"AIS after EVT group","This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"GENETIC","Sequencing of circRNA\u002FlncRNA\u002FmiRNA","Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)",[15,9],[25],"Quantitative Real-time polymerase chain reaction",[27],{"name":28,"affiliation":5,"role":29},"Junshan Zhou, M.D","STUDY_CHAIR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","+8602587726218","zhjsh333@126.com",{"name":36,"role":32,"phone":33,"phoneExt":10,"email":37},"Qiwen Deng, M.D","qiw_deng@163.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Nanjing","Jiangsu","210006","China","CN",{"type":47,"coordinates":48},"Point",[49,50],118.77778,32.06167,{"lat":50,"lon":49},[53,56],{"name":54,"role":32,"phone":55,"phoneExt":10,"email":34},"Junshan Zhou, M.D.","+86025-87726218",{"name":57,"role":32,"phone":55,"phoneExt":10,"email":37},"Qiwen Deng, M.D.",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[61],{"name":62,"class":6},"Zhongda Hospital","100380222","circulating-non-coding-rna-in-acute-ischemic-stroke-with-endovascular-treatment-evtrna-100380222",false,"NCT04230785","Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","EVTRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 24 hours of symptom onset and treat with endovascular therapy\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n* a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases","ALL","18 Years","90 Years",{"count":75,"type":76},300,"ESTIMATED","90 Days","OBSERVATIONAL","EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and\u002For after endovascular treatment. The candidate circRNA\u002FlncRNA\u002FmiRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.",[81,82,83],"Stroke, Acute","Stroke, Ischemic","Endovascular Treatment",[85,86,87,88,89],"acute ischemic stroke","noncoding RNA","endovascular treatment","clinical significance","outcome","2026-04-06",{"date":92,"type":93},"2026-04-09","ACTUAL",{"date":95,"type":93},"2020-03-15",{"date":97,"type":76},"2026-12-01",{"name":5,"class":6},1]